Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event. The clinical-stage biopharmaceutical company's leadership team will deliver a corporate overview presentation on Tuesday, February 11, 2025, at 9:20 am ET.
The company will also conduct one-on-one meetings with investors during the conference. A webcast of the presentation will be accessible through the investor relations section of Corvus's website, with availability both live and for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – CRVS
On the day this news was published, CRVS gained 5.33%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access the CRVS Oppenheimer Conference presentation?
What type of meetings will CRVS conduct at the Oppenheimer Healthcare Conference?
Is the Oppenheimer Healthcare Conference 2025 where CRVS is presenting an in-person event?
